Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Operating Income Loss of -$9.95 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +14.9% in Operating Income Loss from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Operating Income Loss has declined by 514.7%.
- Historical annual values: Fiscal year 2025: -$9.95 million | Fiscal year 2024: -$11.69 million | Fiscal year 2023: -$21.44 million | Fiscal year 2022: -$24.82 million | Fiscal year 2021: -$24.54 million | Fiscal year 2020: -$31.68 million | Fiscal year 2019: -$23.00 million | Fiscal year 2018: -$14.06 million | Fiscal year 2017: -$5.00 million | Fiscal year 2016: -$5.08 million | Fiscal year 2015: -$8.54 million | Fiscal year 2014: -$7.42 million | Fiscal year 2013: -$4.90 million | Fiscal year 2012: -$3.43 million | Fiscal year 2011: -$3.91 million | Fiscal year 2010: $2.40 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: